Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades incretin hormones. By preserving incretins, it enhances glucose‑dependent insulin release and reduces glucagon secretion, complementing metformin’s action of decreasing hepatic glucose production and improving insulin sensitivity.

The specific dose is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and prior response to therapy. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data are limited. The product should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with separate metformin or other DPP‑4 inhibitors, this fixed‑dose combination offers the convenience of a single tablet and synergistic glucose‑lowering effects. It may reduce pill burden versus taking each component separately, while maintaining a safety profile similar to its individual constituents.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Do not refrigerate or freeze. Keep out of reach of children and dispose of any expired product according to local regulations.

The medication is taken orally, usually once daily with food to improve gastrointestinal tolerance. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include lactic acidosis (particularly in patients with renal impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, acute pancreatitis, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

The combination is contraindicated in patients with known hypersensitivity to linagliptin, metformin, or any excipients, as well as those with severe renal impairment (eGFR <30 mL/min/1.73 m²) or a history of lactic acidosis. It should also be avoided in patients with acute or chronic metabolic acidosis.